In Silico Molecular Docking Analysis of Karanjin against Alzheimer's and Parkinson's Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy.
ADMET
Alzheimer’s disease
Lipinski’s rule
Parkinson’s disease
bioinformatics
drug-likeness
in silico
karanjin
molecular dynamics
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
29 Apr 2022
29 Apr 2022
Historique:
received:
09
03
2022
revised:
21
04
2022
accepted:
25
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
18
5
2022
Statut:
epublish
Résumé
Parkinson's disease (PD) and Alzheimer's disease (AD) are neurodegenerative disorders that have emerged as among the serious health problems of the 21st century. The medications currently available to treat AD and PD have limited efficacy and are associated with side effects. Natural products are one of the most vital and conservative sources of medicines for treating neurological problems. Karanjin is a furanoflavonoid, isolated mainly from
Identifiants
pubmed: 35566187
pii: molecules27092834
doi: 10.3390/molecules27092834
pmc: PMC9100660
pii:
doi:
Substances chimiques
Benzopyrans
0
karanjin
WV7IM0I02M
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Mol Graph Model. 2019 Sep;91:91-104
pubmed: 31202091
Mov Disord. 2014 Nov;29(13):1583-90
pubmed: 24976103
Front Aging Neurosci. 2017 May 30;9:168
pubmed: 28611658
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
pubmed: 10592235
J Biomol Struct Dyn. 2019 Aug;37(12):3259-3268
pubmed: 30088792
Mol Neurobiol. 2016 Dec;53(10):7028-7036
pubmed: 26671619
Front Pharmacol. 2019 Nov 26;10:1417
pubmed: 31849668
Transl Neurodegener. 2013 Sep 08;2(1):19
pubmed: 24011391
NPJ Parkinsons Dis. 2017 Apr 10;3:14
pubmed: 28649614
CNS Drug Rev. 2007 Fall;13(3):352-79
pubmed: 17894650
BMC Complement Altern Med. 2018 Jan 3;18(1):1
pubmed: 29295712
Neurobiol Aging. 2002 Nov-Dec;23(6):1017-22
pubmed: 12470797
ACS Chem Neurosci. 2017 Jul 19;8(7):1519-1529
pubmed: 28332824
Ayu. 2017 Jan-Jun;38(1-2):76-81
pubmed: 29861598
Sci Rep. 2020 Apr 22;10(1):6839
pubmed: 32322091
J Basic Clin Physiol Pharmacol. 2017 Sep 26;28(5):413-423
pubmed: 28708573
Molecules. 2021 Sep 02;26(17):
pubmed: 34500759
Front Pharmacol. 2017 Dec 04;8:889
pubmed: 29255418
J Parkinsons Dis. 2020;10(3):757-774
pubmed: 32741777
Alzheimers Dement (N Y). 2020 Jul 16;6(1):e12050
pubmed: 32695874
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):3954-3959
pubmed: 29581300
Nat Rev Neurol. 2018 Mar;14(3):126
pubmed: 29391586
Lancet. 2004 Sep 25-Oct 1;364(9440):1169-71
pubmed: 15451225
Drug Target Insights. 2013 Aug 19;7:27-34
pubmed: 24023511
Mov Disord. 2013 Jan;28(1):31-40
pubmed: 23390095
Nat Prod Res. 2019 Nov;33(22):3181-3189
pubmed: 29792335
Lancet. 2004 Sep 25-Oct 1;364(9440):1167-9
pubmed: 15451224
Lancet Neurol. 2010 Nov;9(11):1106-17
pubmed: 20880751
Exp Neurobiol. 2015 Dec;24(4):325-40
pubmed: 26713080
Sci Rep. 2017 Sep 7;7(1):10827
pubmed: 28883518
Environ Toxicol Pharmacol. 2018 Jan;57:131-140
pubmed: 29272792
Mov Disord. 2003 Jan;18(1):19-31
pubmed: 12518297
Biomolecules. 2020 Apr 01;10(4):
pubmed: 32244832
Int J Mol Sci. 2019 Sep 04;20(18):
pubmed: 31487867
Molecules. 2021 Apr 11;26(8):
pubmed: 33920326
J Neurochem. 2008 Mar;104(6):1433-9
pubmed: 18088381
Molecules. 2020 Jun 09;25(11):
pubmed: 32527030
Expert Opin Pharmacother. 2008 Nov;9(16):2759-72
pubmed: 18937611
J Alzheimers Dis. 2010;19(2):621-30
pubmed: 20110607
Curr Opin Biotechnol. 2007 Dec;18(6):478-88
pubmed: 18035532
J Neuropathol Exp Neurol. 1997 Apr;56(4):321-39
pubmed: 9100663
Food Chem Toxicol. 2019 Jun;128:35-45
pubmed: 30935952
Methods Mol Biol. 2018;1705:375-394
pubmed: 29188574
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
pubmed: 11259830
Bioorg Med Chem. 2015 Oct 1;23(19):6486-96
pubmed: 26337020
Neurosci Lett. 2002 Dec 25;335(2):147-9
pubmed: 12459519
Neurology. 2007 Jan 30;68(5):384-6
pubmed: 17082464
Lancet Neurol. 2018 Nov;17(11):928-929
pubmed: 30287052
J Neurol. 2004 Sep;251 Suppl 6:VI/44-6
pubmed: 15675725
Chem Biol Drug Des. 2018 Mar;91(3):817-827
pubmed: 29139199
Sci Rep. 2019 Dec 24;9(1):19745
pubmed: 31875009
Front Pharmacol. 2017 Oct 06;8:697
pubmed: 29056913
Purinergic Signal. 2021 Oct 22;:
pubmed: 34677752
Front Pharmacol. 2017 Jun 07;8:327
pubmed: 28638340
J Biomol Struct Dyn. 2018 Nov;36(15):3938-3957
pubmed: 29281938
Eur J Med Chem. 2019 Sep 1;177:221-234
pubmed: 31151057
Drugs Today (Barc). 2003 Jan;39(1):75-83
pubmed: 12669110
J Cent Nerv Syst Dis. 2017 May 15;9:1179573517709278
pubmed: 28579870
Comput Biol Chem. 2022 Feb;96:107620
pubmed: 34971900
Alzheimers Res Ther. 2014 Dec 24;6(9):89
pubmed: 25621019
J Neural Transm (Vienna). 2002 Mar;109(3):411-20
pubmed: 11956961
Proteins. 2022 Apr 5;:
pubmed: 35384056
Neurology. 2003 Dec 9;61(11 Suppl 6):S32-8
pubmed: 14663007
Eur J Pain. 2013 Jan;17(1):16-27
pubmed: 22528689
Front Pharmacol. 2020 Apr 23;11:356
pubmed: 32390826
J Cell Biochem. 2018 Dec;119(12):9838-9852
pubmed: 30125973
Neurosci Lett. 2005 Mar 22;377(1):37-9
pubmed: 15722183
Molecules. 2020 Sep 05;25(18):
pubmed: 32899576
Mol Neurodegener. 2011 Nov 23;6:79
pubmed: 22112803
Comput Biol Chem. 2020 Oct;88:107328
pubmed: 32688011
J Biol Chem. 2003 Nov 14;278(46):45937-45
pubmed: 12928438
Clin Ther. 2013 Sep;35(9):1271-81
pubmed: 24054704
Chem Biol Drug Des. 2017 Jun;89(6):964-971
pubmed: 27896926
Anesth Analg. 2017 Feb;124(2):582-587
pubmed: 28099324
Front Mol Neurosci. 2011 Oct 31;4:32
pubmed: 22065134
Bioorg Med Chem. 2019 Apr 1;27(7):1195-1210
pubmed: 30808606
Molecules. 2017 Oct 13;22(10):
pubmed: 29027981
Curr Drug Discov Technol. 2021;18(5):e26082020185360
pubmed: 32860362
Front Mol Neurosci. 2011 Aug 26;4:17
pubmed: 21904524
Expert Rev Neurother. 2009 Dec;9(12):1781-9
pubmed: 19951137
Front Aging Neurosci. 2018 Oct 23;10:284
pubmed: 30405389
J Biomol Struct Dyn. 2020 Nov;38(18):5307-5319
pubmed: 31779524
Int J Mol Sci. 2019 Jun 22;20(12):
pubmed: 31234550